University of Vic - Central University of Catalonia

Alentis Therapeutics Appoints Prof. David Jayne and Prof. Josep Tabernero to its Scientific Advisory Board

Retrieved on: 
Wednesday, June 21, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, American Society of Nephrology, AACR, University, Therapy, European Renal Association, Vall, Nephrology, Neoplasm, University of Vic - Central University of Catalonia, University of Cambridge, ESMO, Editorial, Coronavirus Scientific Advisory Board, Editorial Board at The Wall Street Journal, Multimedia, Doctor of Philosophy, Teaching hospital, ASCO, Professor, ANCA, Patient, CLDN1, Renal Association, Vasculitis, Society, Safety, Pharmaceutical industry, Medicine, Fellow of the Academy of Medical Sciences, MD

Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Professor David Jayne, Professor of Clinical Autoimmunity at Cambridge University and Professor Josep Tabernero, Head of Medical Oncology at Vall d’Hebron University Hospital as members of its Scientific Advisory Board.

Key Points: 
  • Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Professor David Jayne, Professor of Clinical Autoimmunity at Cambridge University and Professor Josep Tabernero, Head of Medical Oncology at Vall d’Hebron University Hospital as members of its Scientific Advisory Board.
  • View the full release here: https://www.businesswire.com/news/home/20230621207738/en/
    Dr David Jayne (left) and Dr Josep Tabernero (right) (Photo: Business Wire)
    “We are delighted to welcome David and Josep to our newly formed Scientific Advisory Board,” said Dr. Luigi Manenti, Chief Medical Officer of Alentis.
  • Dr. Jayne is the international leader in the area of clinical research in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis.
  • Dr. David Jayne, Prof. of Clinical Autoimmunity at Cambridge University said: “I have spent the last 25 years investigating new treatments for ANCA-Vasculitis.